Atrial Fibrillation Feasibility Certoparin Trial - AFFECT

Novartis

Status and phase: Completed; Phase 3

Conditions: Persistent Nonvalvular Atrial Fibrillation

Treatments: Drug: Certoparin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00171769

CMEX839BDE01

Details and patient eligibility

About

This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• persistent AF (electrical cardioversion is planned)
• written informed consent

Exclusion criteria

• acute clinical signs of venous thromboembolism
• current oral anticoagulation
• indication for medical cardioversion

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)